Primary chemotherapy in operable breast carcinoma comparing CMF (cyclophosphamide, methotrexate, 5-fluorouracil) with an anthracycline-containing regimen: Short-term responses translated into long-term outcomes

Annals of Oncology

Volumn 16, Issue 9, 2005, Pages 1469-1476

  Cocconi, Giorgio ^a   Di Blasio, B ^a   Boni, C ^b   Bisagni, G ^b   Rondini, E ^b   Bella, M A ^a   Leonardi, F ^a   Savoldi, L ^b   Vallisneri, C ^a   Camisa, R ^a   Bruzzi, P ^c  

^a Azienda Ospedaliera Parma   (Italy)

^b Azienda Ospedaliera   (United Kingdom)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Anthracycline; Breast carcinoma; CMF; Complete response; Outcome; Primary chemotherapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; VINCRISTINE;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; BOLUS INJECTION; BREAST BIOPSY; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RELAPSE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; POSTMENOPAUSE; PREMENOPAUSE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 24044469033     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi278     Document Type: Article

References (29)

1. Scholl SM, Asselain B, Palangie T et al. Neoadjuvant chemotherapy in operable breast cancer. Eur J Cancer 1991; 27: 1668-1671.
2. Ragaz J, Baird R, Rebbeck P et al. Preoperative (neoadjuvant-pre) versus postoperative (post) adjuvant chemotherapy (CT) for stage III breast cancer: Long term analysis of British Columbia randomized trial. Proceed ASCO 1997; 16: 142a (Abstr).
3. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-2685.
4. Makris A, Powles TJ, Ashley SE et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 1998; 9: 1179-1184.
5. Mauriac L, MacGrogan G, Avril A et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with a 124-month median follow-up. Ann Oncol 1999; 10: 47-52.
6. van der Hage JA, van der Velde CJ, Julien JP et al. Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001; 15: 4224-4237.
7. Mauri D, Pavlidis N, Ioannidis JPA. Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis. J Natl Cancer Inst 2005; 97: 188-194.
8. Ferriere JP, Assier I, Cure H et al. Primary chemotherapy in breast cancer: Correlation between tumor response and patient outcome. Am J Clin Oncol 1998; 21: 117-120.
9. Cocconi G, Di Blasio B, Boni C et al. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma. Cancer 2002; 95: 228-235.
10. American Joint Committee on Cancer. Manual for Staging of Cancer, 4th edition. Philadelphia, PA: Lippincott 1992; 149-154.
11. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
12. Cocconi G, Di Blasio B, Alberti G et al. Problems in evaluating response of primary breast cancer to systemic therapy. Breast Cancer Res Treat 1984; 4: 309-313.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
14. Cox DR. The regression analysis of binary sequences. J R Stat Soc B 1958; 20: 215-242.
15. DeVita VT Jr. Primary chemotherapy can avoid mastectomy, but there is more to it than that. J Natl Cancer Inst 1990; 82: 1522-1524.
16. Fisher B, Mamounas EP. Preoperative chemotherapy: A model for studying the biology and therapy of primary breast cancer. J Clin Oncol 1995; 13: 537-540.
17. Thomas E, Holmes FA, Smith TL et al. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathological response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer. Long-term results from a prospective randomized trial. J Clin Oncol 2004; 22: 2294-2302.
18. Smith IC, Heys SD, Hutcheon AW et al. Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol 2002; 20: 1456-1466.
19. Misset JL, di Palma M, Delgado M et al. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: Final report after a 16-year median follow-up duration. J Clin Oncol 1996; 14: 1136-1145.
20. Mouridsen HT, Andersen J, Andersson M et al. Adjuvant anthracycline in breast cancer improves outcome in premenopausal patients following substitution of methotrexate in the CMF combination with epirubicin. Proceed ASCO 1999; 18: 68a (Abstr).
21. Cocconi G. Adjuvant chemotherapy in early breast cancer: Optimal and suboptimal anthracycline-containing regimens. Breast Cancer Res Treat 2003; 80: 313-320.
22. Fisher B, Redmond C, Wickerham DL et al. Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 1989; 7: 572-582.
23. Hutchins L, Green S, Ravdin P et al. CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: first results of Intergroup Trial INT 0102. Proceed ASCO 1998; 17: 1a (Abstr).
24. Levine MN, Bramwell VH, Pritchard KI et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 1998; 16: 2651-2659.
25. Martin M, Villar A, Solé-Calvo A et al. FAC versus CMF as adjuvant treatment for operable breast cancer: A GEICAM study. Proceed ASCO 2001; 20: 32a (Abstr).
26. Beuzeboc P, Mosseri V, Scholl S et al. Adriamycin based combination chemotherapy significantly improves overall survival in high risk premenopausal breast cancer patients. Breast Cancer Res Treatment 1991; 11: 166 (Abstr).
27. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: An overview of randomised trials. Lancet 1998; 352: 930-942.
28. Tormey DC, Weinberg VE, Holland JF et al. A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer. A CALGB Study. J Clin Oncol 1983; 1: 138-145.
29. Domenech GH, Vogel CL. A review of vinorelbine in the treatment of breast cancer. Clin Breast Cancer 2001; 2: 113-128.